Novartis taps Alteogen’s ALT-B4 for SC drug delivery in $3B deal
Novartis AG is the latest big pharma to turn to Alteogen Inc. to convert biologic drugs into subcutaneous…
Alteogen Signs $3.2 Billion Licensing Deal With Novartis
A view of Alteogen’s headquarters and research center. Photo courtesy of Alteogen Alteogen (196170.KQ) has signed a technology…
Alteogen Signs Up to $3.2 Billion Subcutaneous Injection Technology Export Deal with Novartis — BigGo Finance
Biopharmaceutical platform company Alteogen announced on September 2 that it has signed a technology export agreement with Swiss…
Alteogen Licenses ALT-B4 Platform to Novartis in Deal Worth Up to $3.2 Billion
An exterior view of Alteogen’s headquarters and research center. Photo courtesy of Alteogen Alteogen (196170) has signed a…